NASDAQ:PMVP

PMV Pharmaceuticals (PMVP) Stock Forecast, Price & News

$6.02

-0.68 (-10.15%)

(As of 01:21 PM ET)

Compare

Today's Range: $6.00
▼
$6.86
50-Day Range: $6.02
▼
$8.93
52-Week Range: $3.84
▼
$13.02

Volume: 149,193 shs
Average Volume: 487,089 shs
Market Capitalization: $291.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.00

PMV Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 237.4% Upside
$22.00 Price Target
Short Interest: Bearish
16.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.65
Based on 2 Articles This Week
Insider Trading: Selling Shares
$27,168 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.67) to ($1.92) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.34 out of 5 stars

Medical Sector

921st out of 964 stocks

Pharmaceutical Preparations Industry

434th out of 449 stocks

3.5

Analyst's Opinion

Consensus Rating
PMV Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.00, PMV Pharmaceuticals has a forecasted upside of 237.4% from its current price of $6.52.
Amount of Analyst Coverage
PMV Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
16.34% of the float of PMV Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
PMV Pharmaceuticals has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
Change versus previous month
Short interest in PMV Pharmaceuticals has recently increased by 0.55%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
PMV Pharmaceuticals does not currently pay a dividend.
Dividend Growth
PMV Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PMVP.

0.8

News and Social Media Coverage

News Sentiment
PMV Pharmaceuticals has a news sentiment score of -0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PMV Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,168.00 in company stock.
Percentage Held by Insiders
Only 7.60% of the stock of PMV Pharmaceuticals is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PMV Pharmaceuticals is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PMV Pharmaceuticals is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PMV Pharmaceuticals has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About PMV Pharmaceuticals (NASDAQ:PMVP) Stock

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing Wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q, and R282W, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

PMVP Price History

30 days | 90 days | 365 days | Advanced Chart

PMVP Stock News Headlines

September 20, 2023 | finance.yahoo.com

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

August 30, 2023 | finance.yahoo.com

Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet

September 22, 2023 | UNKNOWN (Ad)

Bringing Space Down to Earth

Cutting edge, AI-powered, Space-based Earth-observation solutions

August 29, 2023 | finance.yahoo.com

PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden Cross

August 11, 2023 | msn.com

HC Wainwright & Co. Maintains PMV Pharmaceuticals (PMVP) Buy Recommendation

August 9, 2023 | finanznachrichten.de

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

August 9, 2023 | finance.yahoo.com

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

June 20, 2023 | finance.yahoo.com

PMVP Jul 2023 5.000 call

September 22, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

June 10, 2023 | morningstar.com

PMV Pharmaceuticals Inc Ordinary Shares

May 17, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for PMV Pharma

May 17, 2023 | msn.com

HC Wainwright & Co. Reiterates PMV Pharmaceuticals (PMVP) Buy Recommendation

May 12, 2023 | msn.com

Oppenheimer Reiterates PMV Pharmaceuticals (PMVP) Outperform Recommendation

May 11, 2023 | marketwatch.com

8-K: PMV Pharmaceuticals, Inc.

May 10, 2023 | finanznachrichten.de

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

May 10, 2023 | finance.yahoo.com

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

March 27, 2023 | msn.com

Wall Street’s 10 most shorted stocks right now, including Silvergate and WeWork

March 20, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for PMV Pharmaceuticals (PMVP)

March 1, 2023 | benzinga.com

PMV Pharmaceuticals shares are trading lower after the company reported FY22 financial results.

March 1, 2023 | finance.yahoo.com

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

March 1, 2023 | finance.yahoo.com

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

February 22, 2023 | finance.yahoo.com

Veterinary Pharmaceuticals Global Market Opportunities And Strategies To 2031

February 17, 2023 | nasdaq.com

Rtw Investments Now Owns 9.50% of PMV Pharmaceuticals (PMVP)

December 8, 2022 | finance.yahoo.com

Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect?

November 22, 2022 | finance.yahoo.com

PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

November 8, 2022 | finanznachrichten.de

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

November 8, 2022 | finance.yahoo.com

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

See More Headlines

Receive PMVP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PMVP Company Calendar

Last Earnings: 8/09/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PMVP
CUSIP: N/A
CIK: 1699382
Web: www.pmvpharma.com
Phone: 609-642-6670
Fax: N/A
Employees: 62
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $22.00
High Stock Price Forecast: $29.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +228.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-73,320,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -31.05%
Return on Assets: -28.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.63
Quick Ratio: 16.63

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.39 per share
Price / Book: 1.24

Miscellaneous

Outstanding Shares: 48,460,000
Free Float: 44,772,000
Market Cap: $324.92 million
Optionable: Not Optionable
Beta: 0.93

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. David H. Mack Ph.D. (Age 61)
Co-Founder, CEO, Pres & Director
Comp: $762.02k

Dr. Arnold J. Levine Ph.D. (Age 83)
Co-Founder, Director & Member of Scientific Advisory Board
Comp: $140k

Mr. Winston Kung M.B.A. (Age 47)
COO & CFO
Comp: $591.29k

Dr. Leila Alland M.D. (Age 60)
Chief Medical Officer
Comp: $601.93k

Dr. Thomas E. Shenk Ph.D. (Age 76)
Co-Founder & Member of Scientific Advisory Board

Mr. Robert Ticktin (Age 61)
Gen. Counsel & Company Sec.

Mr. Tim Smith
Sr. VP & Head of Corp. Devel.

Ms. Crystal Zuckerman
VP of HR

Dr. Binh Vu Ph.D.
Sr. VP of Drug Discovery & CMC

Dr. Deepika Jalota Pharm.D. (Age 46)
Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PMVP Stock - Frequently Asked Questions

Should I buy or sell PMV Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PMVP shares.
View PMVP analyst ratings or view top-rated stocks.
What is PMV Pharmaceuticals' stock price forecast for 2023?: 2 analysts have issued 1-year price targets for PMV Pharmaceuticals' shares. Their PMVP share price forecasts range from $15.00 to $29.00. On average, they predict the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 228.1% from the stock's current price.
View analysts price targets for PMVP or view top-rated stocks among Wall Street analysts.
How have PMVP shares performed in 2023?: PMV Pharmaceuticals' stock was trading at $8.70 at the beginning of 2023. Since then, PMVP stock has decreased by 22.9% and is now trading at $6.7050.
View the best growth stocks for 2023 here.
When is PMV Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our PMVP earnings forecast.
How were PMV Pharmaceuticals' earnings last quarter?: PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09.
What ETFs hold PMV Pharmaceuticals' stock?: ETFs with the largest weight of PMV Pharmaceuticals (NASDAQ:PMVP) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).IQ Chaikin U.S. Small Cap ETF (CSML).

What other stocks do shareholders of PMV Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN), Akoustis Technologies (AKTS), Agios Pharmaceuticals (AGIO), Admiral Group (ADM) and Adobe (ADBE).
When did PMV Pharmaceuticals IPO?: (PMVP) raised $126 million in an initial public offering on Friday, September 25th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO.
What is PMV Pharmaceuticals' stock symbol?: PMV Pharmaceuticals trades on the NASDAQ under the ticker symbol "PMVP."
Who are PMV Pharmaceuticals' major shareholders?: PMV Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.22%), JPMorgan Chase & Co. (8.90%), Principal Financial Group Inc. (2.02%), Geode Capital Management LLC (1.63%), Woodline Partners LP (1.51%) and Bank of Montreal Can (1.53%). Insiders that own company stock include Arnold J Levine, Arnold J Levine, David Henry Mack, Deepika Jalota, Euclidean Capital Llc, Laszlo Kopits, Leila Alland, Ling Zang, Orbimed Advisors Llc, Paul Klauder, Ra Capital Management, LP, Richard A Heyman, Thilo Schroeder and Winston Kung.
View institutional ownership trends.
How do I buy shares of PMV Pharmaceuticals?: Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is PMV Pharmaceuticals' stock price today?: One share of PMVP stock can currently be purchased for approximately $6.71.
How much money does PMV Pharmaceuticals make?: PMV Pharmaceuticals (NASDAQ:PMVP) has a market capitalization of $324.92 million. The company earns $-73,320,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.
How can I contact PMV Pharmaceuticals?: The official website for the company is www.pmvpharma.com. The company can be reached via phone at 609-642-6670 or via email at investors@pmvpharma.com.

This page (NASDAQ:PMVP) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial